Core Viewpoint - Dongyao Pharmaceutical-B (01875) announced significant changes in its executive leadership, effective October 11, 2025, with Mr. Fu Shan transitioning from a non-executive director to an executive director, while Dr. Liu Jun and Ms. Huang Chunying will resign from their respective positions due to personal reasons [1]. Group 1: Leadership Changes - Mr. Fu Shan will lead and oversee the management and development of the group after his transition to executive director [1]. - Dr. Liu Jun will resign from his roles as executive director, CEO, chief scientific officer, and member of the strategic and ESG committee due to personal reasons [1]. - Ms. Huang Chunying will resign from her positions as non-executive director, vice-chairman, and member of the strategic and ESG committee, also due to personal reasons [1]. Group 2: Compliance and Representation - Following Dr. Liu's departure, Mr. Fu Shan has been appointed as the company's authorized representative in accordance with Listing Rule 3.05, effective from October 11, 2025 [1].
东曜药业-B：付山由非执行董事调任为执行董事